• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.

作者信息

Coster T S, Killeen K P, Waldor M K, Beattie D T, Spriggs D R, Kenner J R, Trofa A, Sadoff J C, Mekalanos J J, Taylor D N

机构信息

Clinical Studies Branch, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011, USA.

出版信息

Lancet. 1995 Apr 15;345(8955):949-52. doi: 10.1016/s0140-6736(95)90698-3.

DOI:10.1016/s0140-6736(95)90698-3
PMID:7715293
Abstract

New vaccines are needed to prevent cholera caused by Vibrio cholerae O139. Attenuated V cholerae O139 vaccines were made by deleting multiple copies of the cholera-toxin genetic element from two virulent strains of the organism, MO10 and AI4456. The deletion mutants were further modified by insertion of a construct that encoded the B subunit of cholera toxin, thus generating strains Bengal-3 and VRI-16. A stable spontaneous non-motile derivative of Bengal-3 was isolated and designated Bengal-15; VRI-16 is naturally non-motile. Bengal-3, Bengal-15, and VRI-16 were evaluated as oral single-dose cholera vaccine candidates in 4 volunteers each, and MO10 was given to 3 volunteers. 1 of 4 volunteers who received Bengal-3 and all 3 who received MO10 had diarrhoea. VRI-16 caused no significant symptoms but was not immunogenic. Bengal-15 produced few symptoms and was nearly as immunogenic as MO10. Subsequently, Bengal-15 was given to 10 volunteers at a dose of 10(8) colony-forming units. No volunteers had diarrhoea, and other subjective symptoms were as common in vaccinees as in 3 buffer recipients. 1 month after vaccination, 7 vaccinees, the 3 buffer recipients, and 3 unimmunised subjects were challenged with 5 x 10(6) colony-forming units of V cholerae O139. 5 of 6 controls had cholera-like diarrhoea. By contrast, 1 of 7 vaccinees had diarrhoea, which was mild and had a long incubation period. Vaccine protective efficacy was 83%. Our results indicate the Bengal-15 is a safe live attenuated vaccine candidate for cholera caused by the O139 serogroup.

摘要

相似文献

1
Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
Lancet. 1995 Apr 15;345(8955):949-52. doi: 10.1016/s0140-6736(95)90698-3.
2
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.单剂量口服霍乱活疫苗CVD 103-HgR接种三个月后,用霍乱弧菌O1 El tor稻叶型毒株攻击,预防霍乱效果的随机、双盲、安慰剂对照、多中心试验。
Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999.
3
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.候选疫苗霍乱弧菌638对健康志愿者具有霍乱预防作用。
Infect Immun. 2005 May;73(5):3018-24. doi: 10.1128/IAI.73.5.3018-3024.2005.
4
Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.用二价B亚单位-O1/O139全细胞霍乱疫苗口服免疫后人体的肠道和全身免疫反应
Vaccine. 1996 Oct;14(15):1459-65. doi: 10.1016/s0264-410x(96)00071-0.
5
Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.在冷链外储存 140 天后,一种口服霍乱活疫苗制剂的免疫原性和保护效力。
BMC Immunol. 2020 May 25;21(1):29. doi: 10.1186/s12865-020-00360-1.
6
Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.秘鲁-15,一种用于霍乱弧菌O1型的改良口服减毒活疫苗候选株。
J Infect Dis. 1995 Oct;172(4):1126-9. doi: 10.1093/infdis/172.4.1126.
7
Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.口服霍乱活疫苗候选株CVD 110(埃尔托小川型霍乱弧菌的ctxA缺失、zot缺失、ace缺失衍生物)的安全性和免疫原性
J Infect Dis. 1993 Dec;168(6):1536-40. doi: 10.1093/infdis/168.6.1536.
8
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.在感染 O139 霍乱弧菌和接种商业双价口服霍乱疫苗后,针对人类 O139 霍乱弧菌的多糖特异性抗体靶点的定义,以及针对 O139 的结合疫苗的评估。
mSphere. 2021 Aug 25;6(4):e0011421. doi: 10.1128/mSphere.00114-21. Epub 2021 Jul 7.
9
Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.德克萨斯之星-SR:减毒口服霍乱弧菌候选疫苗
Dev Biol Stand. 1983;53:59-65.
10
Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.单剂量减毒口服霍乱疫苗Peru-15安全性、免疫原性及保护效力的随机对照人体激发试验
Infect Immun. 2002 Apr;70(4):1965-70. doi: 10.1128/IAI.70.4.1965-1970.2002.

引用本文的文献

1
Transcriptome Analysis Reveals Cross-Talk between the Flagellar Transcriptional Hierarchy and Secretion System in .转录组分析揭示了. 鞭毛转录层级与分泌系统之间的串扰
Int J Mol Sci. 2024 Jul 5;25(13):7375. doi: 10.3390/ijms25137375.
2
DegS protease regulates the motility, chemotaxis, and colonization of .DegS蛋白酶调节……的运动性、趋化性和定殖。 (原文此处不完整,缺少具体所指对象)
Front Microbiol. 2023 Apr 5;14:1159986. doi: 10.3389/fmicb.2023.1159986. eCollection 2023.
3
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.
抗击传染病的军事医学策略历史回顾:从战场到全球健康
Biomedicines. 2022 Aug 22;10(8):2050. doi: 10.3390/biomedicines10082050.
4
Human Challenge Studies for Cholera.人类霍乱挑战研究。
Curr Top Microbiol Immunol. 2024;445:177-188. doi: 10.1007/82_2022_258.
5
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.在感染 O139 霍乱弧菌和接种商业双价口服霍乱疫苗后,针对人类 O139 霍乱弧菌的多糖特异性抗体靶点的定义,以及针对 O139 的结合疫苗的评估。
mSphere. 2021 Aug 25;6(4):e0011421. doi: 10.1128/mSphere.00114-21. Epub 2021 Jul 7.
6
Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.在冷链外储存 140 天后,一种口服霍乱活疫苗制剂的免疫原性和保护效力。
BMC Immunol. 2020 May 25;21(1):29. doi: 10.1186/s12865-020-00360-1.
7
Flagellar Synthesis.鞭毛合成。
Front Cell Infect Microbiol. 2019 May 1;9:131. doi: 10.3389/fcimb.2019.00131. eCollection 2019.
8
Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.构建并评价霍乱弧菌 O139 突变株 VCUSM21P 作为一种安全的减毒活霍乱疫苗。
PLoS One. 2014 Feb 5;9(2):e81817. doi: 10.1371/journal.pone.0081817. eCollection 2014.
9
The utility of human challenge studies in vaccine development: lessons learned from cholera.人体激发试验在疫苗研发中的应用:霍乱研究的经验教训
Vaccine (Auckl). 2011 Oct;2011(1):3-13. doi: 10.2147/VDT.S23634.
10
Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.基于外膜囊泡的霍乱疫苗候选物的脂多糖修饰降低了内毒素毒性,并揭示了主要保护性抗原。
Infect Immun. 2013 Jul;81(7):2379-93. doi: 10.1128/IAI.01382-12. Epub 2013 Apr 29.